Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2013 (2013), Article ID 683964, 12 pages
http://dx.doi.org/10.1155/2013/683964
Review Article

Everolimus in Heart Transplantation: An Update

1Department of Cardiothoracic Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany
2Division of Cardiovascular,Thoracic and Transplantation Surgery, Hannover Medical School, Carl-Neuberg-Straße 1, 30625 Hannover, Germany
3Department of Cardiac Surgery, University Hospital Leipzig, Heart Center, 04289 Leipzig, Germany
4Department of Cardiovascular Surgery, University Heart Center Hamburg, Martinistr 52, 20246 Hamburg, Germany
5Department of Cardiology, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany
6Department of Cardiac Surgery, Munich Transplantation Center, Klinikum Großhadern LMU, Marchioninistraße 15, 81377 Munich, Germany
7Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Georgstraße 11, 32545 Bad Oeynhausen, Germany
8Department of Cardiovascular Medicine, Division of Cardiology, Münster University Hospital, Albert-Schweitzer-Straße 33, 48149 Münster, Germany
9Department of Cardiovascular Surgery, University Hospital Kiel, Arnold-Heller-Straße 7, 24105 Kiel, Germany
10Department of Cardiovascular and Thoracic Surgery, German Heart Institute Berlin, Augustenburger Platz 1, 13353 Berlin, Germany

Received 3 August 2013; Revised 27 September 2013; Accepted 29 September 2013

Academic Editor: Eric Thervet

Copyright © 2013 Stephan W. Hirt et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. I. Sánchez-Fructuoso, “Everolimus: an update on the mechanism of action, pharmacokinetics and recent clinical trials,” Expert Opinion on Drug Metabolism and Toxicology, vol. 4, no. 6, pp. 807–819, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. H. J. Eisen, E. M. Tuzcu, R. Dorent et al., “Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients,” The New England Journal of Medicine, vol. 349, no. 9, pp. 847–858, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Hummel, “Recommendations for use of Certican (everolimus) after heart transplantation: results from a German and Austrian Consensus Conference,” Journal of Heart & Lung Transplantation, vol. 24, no. 4, supplement, pp. S196–S200, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Rothenburger, A. Zuckermann, C. Bara et al., “Recommendations for the use of Everolimus (Certican) in heart transplantation: results from the Second German-Austrian Certican Consensus Conference,” Journal of Heart & Lung Transplantation, vol. 26, no. 4, pp. 305–311, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. H. B. Lehmkuhl, J. Arizon, M. Viganò et al., “Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients,” Transplantation, vol. 88, no. 1, pp. 115–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Gullestad, M. Iversen, S.-A. Mortensen et al., “Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial,” Transplantation, vol. 89, no. 7, pp. 864–872, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Potena, I. G. Bianchi, G. Magnani et al., “Cyclosporine lowering with everolimus or mycophenolate to preserve renal function in heart recipients: a randomized study,” Transplantation, vol. 89, no. 2, pp. 263–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. L. Potena, P. Prestinenzi, I. G. Bianchi et al., “Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study,” Journal of Heart & Lung Transplantation, vol. 31, no. 6, pp. 565–570, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. H. J. Eisen, J. Kobashigawa, R. C. Starling et al., “Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial,” American Journal of Transplantation, vol. 13, no. 5, pp. 1203–1216, 2013. View at Google Scholar
  10. H. B. Lehmkuhl, D. Mai, M. Dandel et al., “Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients,” Journal of Heart & Lung Transplantation, vol. 26, no. 7, pp. 700–704, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Manito, J. F. Delgado, M. G. Crespo-Leiro et al., “Clinical recommendations for the use of everolimus in heart transplantation,” Transplantation Reviews, vol. 24, no. 3, pp. 129–142, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. B. Nashan and F. Citterio, “Wound healing complications and the use of mTOR inhibitors in kidney transplantation—a critical review of the literature,” Transplantation, vol. 94, no. 6, pp. 547–561, 2012. View at Google Scholar
  13. A. Zuckermann, J. M. Arizon, G. Dong et al., “Impact of de novo everolimus-based immunosuppression on incisional complications in heart transplantation,” Transplantation, vol. 92, no. 5, pp. 594–600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Potena, M. Rinaldi, C. Maiello et al., “81 Early vs delayed everolimusin de novo heart transplant recipients,” Journal of Heart & Lung Transplantation, vol. 30, no. 4, supplement, p. S35, 2011. View at Google Scholar
  15. J. Kobashigawa, H. Ross, C. Bara et al., “Everolimus is associated with a reduced incidence of cytomegalovirus infection following de novo cardiac transplantation,” Transplant Infectious Diseasess, vol. 15, no. 2, pp. 150–162, 2013. View at Google Scholar
  16. U. Fuchs, A. Zittermann, K. Hakim-Meibodi, J. Brgermann, U. Schulz, and J. F. Gummert, “Everolimus plus dosage reduction of cyclosporine in cardiac transplant recipients with chronic kidney disease: a two-year follow-up study,” Transplantation Proceedings, vol. 43, no. 5, pp. 1839–1846, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. U. Fuchs, A. Zittermann, U. Schulz, and J. F. Gummert, “Efficacy and safety of low-dose everolimusas maintenance immunosuppression in cardiac transplant recipients,” Journal of Transplantation, vol. 2012, Article ID 976921, 7 pages, 2012. View at Publisher · View at Google Scholar
  18. Š. Vítko, R. Margreiter, W. Weimar et al., “Everolimus (certican) 12-month safety and efficacy versus mycophenolate mofetil in de Novo renal transplant recipients,” Transplantation, vol. 78, no. 10, pp. 1532–1540, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Stypmann, M. A. Engelen, S. Eckernkemper et al., “Calcineurin inhibitor-free immunosuppression using everolimus (certican) after heart transplantation: 2 years' follow-up from the university hospital Münster,” Transplantation Proceedings, vol. 43, no. 5, pp. 1847–1852, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Viganò, M. Tuzcu, R. Benza et al., “Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplants recipients: a 24-month analysis,” Journal of Heart & Lung Transplantation, vol. 26, no. 6, pp. 584–592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. M. R. Mehra, H. O. Ventura, D. D. Stapleton, F. W. Smart, T. C. Collins, and S. R. Ramee, “Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy,” Journal of Heart & Lung Transplantation, vol. 14, no. 4, pp. 632–639, 1995. View at Google Scholar · View at Scopus
  22. J. A. Kobashigawa, J. M. Tobis, R. C. Starling et al., “Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years,” Journal of the American College of Cardiology, vol. 45, no. 9, pp. 1532–1537, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. M. R. Costanzo, A. Dipchand, R. Starling et al., “The international society of heart and lung transplantation guidelines for the care of heart transplant recipients,” Journal of Heart & Lung Transplantation, vol. 29, no. 8, pp. 914–956, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Valantine, “Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology,” Journal of Heart & Lung Transplantation, vol. 26, no. 6, pp. 557–564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. J. Motzer, B. Escudier, S. Oudard et al., “Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial,” The Lancet, vol. 372, no. 9637, pp. 449–456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. R. J. Motzer, B. Escudier, S. Oudard et al., “Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors,” Cancer, vol. 116, no. 18, pp. 4256–4265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. M. Campistol and F. P. Schena, “Kaposi's sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors,” Nephrology Dialysis Transplantation, vol. 22, no. 1, pp. i17–i22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Fernández, R. Marcén, J. Pascual et al., “Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia,” Transplantation Proceedings, vol. 38, no. 8, pp. 2453–2455, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Chiurchiu, C. A. Carreño, R. Schiavelli et al., “Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies,” Transplantation Proceedings, vol. 42, no. 1, pp. 277–279, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. D. Tiberio, D. N. Franz, and J. R. Phillips, “Regression of a cardiac rhabdomyoma in a patient receiving everolimus,” Pediatrics, vol. 127, no. 5, pp. e1335–e1337, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kusuki, Y. Hashii, N. Fukushima et al., “Pediatric post-transplant diffuse large B cell lymphoma after cardiac transplantation,” International Journal of Hematology, vol. 89, no. 2, pp. 209–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Euvrard, P. Boissonnat, A. Roussoulières et al., “Effect of everolimus on skin cancers in calcineurin inhihitor-treated heart transplant recipients,” Transplant International, vol. 23, no. 8, pp. 855–857, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. M. Sarwal, “Out with the old, in with the new: immunosuppression minimization in children,” Current Opinion in Organ Transplantation, vol. 13, no. 5, pp. 513–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Höcker and B. Tönshoff, “Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?” Paediatr Drugs, vol. 13, no. 1, pp. 49–69, 2011. View at Google Scholar
  35. S. W. Denfield, “Strategies to prevent cellular rejection in pediatric heart transplant recipients,” Pediatric Drugs, vol. 12, no. 6, pp. 391–403, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Behnke-Hall, J. Bauer, J. Thul et al., “Renal function in children with heart transplantation after switching to CNI-free immunosuppression with everolimus,” Pediatric Transplantation, vol. 15, no. 8, pp. 784–789, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Pape, G. Offner, M. Kreuzer et al., “De novo therapy with everolimus, low-dose ciclosporine a, basiliximab and steroid elimination in pediatric kidney transplantation,” American Journal of Transplantation, vol. 10, no. 10, pp. 2349–2354, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Kovarik, A. Noe, S. Berthier et al., “Clinical development of an everolimus pediatric formulation: relative bioavailability, food effect, and steady-state pharmacokinetics,” Journal of Clinical Pharmacology, vol. 43, no. 2, pp. 141–147, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Ettenger, P.-F. Hoyer, P. Grimm et al., “Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year,” Pediatric Transplantation, vol. 12, no. 4, pp. 456–463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. N. K. Kanzelmeyer, T. Ahlenstiel, J. Drube et al., “Protocol biopsy-driven interventions after pediatric renal transplantation,” Pediatric Transplantation, vol. 14, no. 8, pp. 1012–1018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Pape, F. Lehner, C. Blume, and T. Ahlenstiel, “Pediatric kidney transplantation followed by de novo therapy with everolimus, low-dose cyclosporine a, and steroid elimination: 3-year data,” Transplantation, vol. 92, no. 6, pp. 658–662, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Grushkin, J. D. Mahan, K. C. Mange, J. M. Hexham, and R. Ettenger, “De novo therapy with everolimusand reduced-exposure cyclosporine following pediatric kidney transplantation: a prospective, multicenter, 12-month study,” Pediatric Transplantation, vol. 17, no. 3, pp. 237–243, 2013. View at Google Scholar
  43. D. Nielsen, A. Briem-Richter, M. Sornsakrin, L. Fischer, B. Nashan, and R. Ganschow, “The use of everolimus in pediatric liver transplant recipients: first experience in a single center,” Pediatric Transplantation, vol. 15, no. 5, pp. 510–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Pascual, D. del Castillo, M. Cabello et al., “Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial,” Transplantation, vol. 89, no. 8, pp. 994–1000, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. Certican Basic Prescribing Information, Novartis Pharma, Switzerland, 2012.
  46. Rapamune Summary of Product Characteristics, Pfizer, New York, NY, USA, 2011.
  47. G. I. Kirchner, I. Meier-Wiedenbach, and M. P. Manns, “Clinical pharmacokinetics of everolimus,” Clinical Pharmacokinetics, vol. 43, no. 2, pp. 83–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Crowe, A. Bruelisauer, L. Duerr, P. Guntz, and M. Lemaire, “Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats,” Drug Metabolism & Disposition, vol. 27, no. 5, pp. 627–632, 1999. View at Google Scholar · View at Scopus
  49. J. M. Kovarik, H. D. Sabia, J. Figueiredo et al., “Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment,” Clinical Pharmacology & Therapeutics, vol. 70, no. 5, pp. 425–430, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. W. Schuler, R. Sedrani, S. Cottens et al., “SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo,” Transplantation, vol. 64, no. 1, pp. 36–42, 1997. View at Publisher · View at Google Scholar · View at Scopus
  51. L. Albano, F. Berthoux, M.-C. Moal et al., “Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus,” Transplantation, vol. 88, no. 1, pp. 69–76, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Zuckermann and M. J. Barten, “Surgical wound complications after heart transplantation,” Transplant International, vol. 24, no. 7, pp. 627–636, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. T. M. Chapman and C. M. Perry, “Everolimus,” Drugs, vol. 64, no. 8, pp. 861–872, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. J. M. Kovarik, J. Kalbag, J. Figueiredo, M. Rouilly, L. F. O'Bannon, and C. Rordorf, “Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction,” Journal of Clinical Pharmacology, vol. 42, no. 1, pp. 95–99, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. J. M. Kovarik, J. J. Curtis, D. E. Hricik, M. D. Pescovitz, V. Scantlebury, and A. Vasquez, “Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus,” Transplantation Proceedings, vol. 38, no. 10, pp. 3456–3458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. U. Fuchs, A. Zittermann, B. Schulze et al., “Clinical results of immunosuppressive therapy in heart transplant recipients receiving tacrolimus and everolimus compared to the combination of cyclosporine A and everolimus,” Transplantation, vol. 90, supplement 2, p. S448, 2010. View at Google Scholar
  57. F. Gonzalez-Vilchez, J. A. Vazquez de Prada, L. Almenar et al., “Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation,” Journal of Heart & Lung Transplantation, vol. 31, no. 3, pp. 288–295, 2012. View at Publisher · View at Google Scholar · View at Scopus